Geron's Cash & cash equivalent grew by 7.74 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Geron's Quick Ratio to 0.94, Quick Ratio remained below Geron Corporation average.

Within Major Pharmaceutical Preparations industry 359 other companies have achieved higher Quick Ratio than Geron in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1581 to 2047.

Explain Quick Ratio?
How much Cash & cash equivalents GERN�s has?
What are GERN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GERN/financial-strength

https://api.csimarket.com/api/v1/companies/GERN/fundamentals

https://api.csimarket.com/api/v1/companies/GERN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GERN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-15.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-12.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.94	Subscribe	Subscribe	Subscribe	Subscribe
GERN's Total Ranking	# 2047	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	5.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	7.74 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 360
Healthcare Sector	# 644
Overall Market	# 2047

Quick Ratio Statistics
High	Average	Low
51.83	13.02	0.71
(Jun 30 2017)		(Dec 31 2025)

Financial Statements
Geron's Current Liabilities	$ 74 Millions	Visit GERN's Balance sheet
Geron's Cash & cash equivalent	$ 70 Millions	Visit GERN's Balance sheet
Source of GERN's Sales		Visit GERN's Sales by Geography

Cumulative Geron's Quick Ratio

GERN's Quick Ratio for the trailling 12 Months

GERN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	8.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-12.84 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.86	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3981	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-3.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-3.46 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GERN Financial Strength Comparisons >> Go to Compare GERN Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in GERN's Current Liabilities to $74.25 millions, cumulative Quick Ratio to 0.86 below the GERN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Geron. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2831 to 3981.

Explain Quick Ratio?
How much Cash & cash equivalents GERN�s has?
What are GERN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 437
Healthcare Sector	# 897
Within the Market	# 3981

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.82	1.32	0.59
(Sep 30 2018)		(Jun 30 2015)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Biohaven Ltd	2.57	$ 161.125 Millions	$ 62.767 Millions
Ironwood Pharmaceuticals inc	2.49	$ 86.376 Millions	$ 34.733 Millions
Azitra Inc	2.44	$ 3.751 Millions	$ 1.540 Millions
Tg Therapeutics Inc	2.43	$ 632.004 Millions	$ 260.526 Millions
Adc Therapeutics Sa	2.42	$ 189.204 Millions	$ 78.125 Millions
Dermata Therapeutics Inc	2.40	$ 4.822 Millions	$ 2.012 Millions
Opko Health Inc	2.37	$ 384.036 Millions	$ 162.356 Millions
Pacira Biosciences inc	2.31	$ 295.577 Millions	$ 128.209 Millions
Dogwood Therapeutics inc	2.28	$ 4.948 Millions	$ 2.174 Millions
Ardelyx inc	2.23	$ 285.338 Millions	$ 127.805 Millions
Schrodinger Inc	2.20	$ 366.358 Millions	$ 166.292 Millions
Stoke Therapeutics Inc	2.19	$ 107.271 Millions	$ 48.977 Millions
Quantum Cyber N v	2.17	$ 5.032 Millions	$ 2.319 Millions
Maravai Lifesciences Holdings Inc	2.14	$ 73.023 Millions	$ 34.160 Millions
Ernexa Therapeutics Inc	2.13	$ 5.575 Millions	$ 2.614 Millions
Madrigal Pharmaceuticals Inc	2.12	$ 962.387 Millions	$ 454.244 Millions
Puma Biotechnology Inc	2.09	$ 108.575 Millions	$ 51.971 Millions
Corcept Therapeutics Inc	2.09	$ 370.703 Millions	$ 177.675 Millions
Biomea Fusion Inc	2.07	$ 26.403 Millions	$ 12.771 Millions
Longeveron Inc	1.96	$ 12.761 Millions	$ 6.527 Millions
Dianthus Therapeutics Inc	1.95	$ 55.686 Millions	$ 28.515 Millions
Xeris Biopharma Holdings Inc	1.95	$ 262.164 Millions	$ 134.479 Millions
Ars Pharmaceuticals Inc	1.95	$ 138.354 Millions	$ 70.995 Millions
Decoy Therapeutics Inc	1.92	$ 8.168 Millions	$ 4.247 Millions
Elite Pharmaceuticals Inc	1.92	$ 34.863 Millions	$ 18.152 Millions
Lite Strategy Inc	1.92	$ 4.281 Millions	$ 2.234 Millions
Mineralys Therapeutics Inc	1.91	$ 101.273 Millions	$ 53.075 Millions
Spero Therapeutics Inc	1.89	$ 107.928 Millions	$ 56.962 Millions
Amarin Corp Plcuk	1.85	$ 323.379 Millions	$ 175.136 Millions
Mustang Bio inc	1.80	$ 14.276 Millions	$ 7.947 Millions

Date modified: 2026-11-05T11:02:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.